Serum High-Sensitivity C-Reactive Protein Levels and the Risk of Atrial Fibrillation in Japanese Population: the Circulatory Risk in Communities Study

Mari Tanaka1, Hironori Imano1,2, Yasuhiko Kubota2, Kazumasa Yamagishi2,3,4, Mitsumasa Umesawa2,3,5, Isao Muraki1,2, Renze Cui1, Mina Hayama-Terada2,6, Yuji Shimizu2, Takeo Okada2, Tetsuya Ohira7, Tomoko Sankai8, Takeshi Tanigawa9, Shinichi Sato10, Akihiko Kitamura1,2,11, Masahiko Kiyama2, Hiroyasu Iso1,2,3,9 and the CIRCS Investigators

1 Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
2 Osaka Center for Cancer and Cardiovascular Disease Prevention, Osaka, Japan
3 Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Ibaraki, Japan
4 Ibaraki Western Medical Center, Ibaraki, Japan
5 Dokkyo Medical University School of Medicine, Tochigi, Japan
6 Yao Public Health Center, Yao City Office, Osaka, Japan
7 Department of Epidemiology, School of Medicine, Fukushima Medical University, Fukushima, Japan
8 Department of Public Health and Nursing, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
9 Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo, Japan
10 Chiba Prefectural Institute of Public Health, Chiba, Japan
11 Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

Aim: This study aimed to investigate the association between the serum high-sensitivity C-reactive protein (hs-CRP) levels and incident atrial fibrillation risk in the general Japanese population, who have lower hs-CRP levels than the Western population, and assess whether the association is modified by sex, overweight, hypertension, and smoking status.

Methods: We conducted a prospective study in 6517 Japanese men and women aged 40–79 years without atrial fibrillation at baseline and enrolled in the Circulatory Risk in Communities Study (2002–2008). The hs-CRP levels were measured using the latex particle-enhanced immunonephelometric assay. Atrial fibrillation was identified using standard 12-lead electrocardiograms and information on physician-diagnosed atrial fibrillation history from the follow-up surveys. We used a Cox proportional hazard regression stratified by community.

Results: During a median follow-up of 11 years, 127 new cases of atrial fibrillation (74 and 53 cases among men and women, respectively) were found. Compared to the lowest quintile of hs-CRP levels, the multivariable hazard ratios (95% confidence intervals) were 2.54 (1.17–5.50), 2.28 (1.06–4.93), 2.92 (1.37–6.23), and 2.77 (1.30–5.91) for the second, third, fourth, and fifth (highest) quintiles, respectively. There was no significant effect modification by sex, overweight, hypertension, and smoking status (P for interaction > 0.05).

Conclusions: Elevated hs-CRP levels were significantly associated with increased risk of atrial fibrillation in the Japanese population. The association of hs-CRP levels with incident atrial fibrillation did not vary according to sex, overweight, hypertension status, or smoking status.

Key words: C-reactive protein, Atrial fibrillation, Risk factor, Cohort study
Introduction

Atrial fibrillation, the most common cardiac arrhythmia in clinical practice, can lead to stroke, heart failure, and other cardiovascular complications\(^1\),\(^2\) and consequently contribute to considerably high mortalities\(^3\),\(^4\). Over a million individuals are expected to be affected with atrial fibrillation by 2050 because of population aging in Japan\(^5\),\(^6\). Therefore, it is important to identify populations at a high risk of developing atrial fibrillation.

In our prospective nested case-control study of a Japanese population, we found that the levels of high-sensitivity C-reactive protein (hs-CRP), a major biomarker of systemic inflammation and atherosclerosis\(^7\), was associated with the risk of ischemic stroke\(^8\). Considering that atrial fibrillation is a common cause of ischemic stroke, the hs-CRP levels could be a predictive marker of atrial fibrillation. In fact, previous cohort studies have reported that the hs-CRP levels predicts atrial fibrillation\(^9\),\(^10\). However, the pathophysiological link between inflammation and the risk of atrial fibrillation remains unclear. Furthermore, only a few long-term population-based cohort studies have examined the association\(^9\),\(^10\),\(^11\), and there is limited evidence among Asian populations\(^14\),\(^15\), which have lower levels of hs-CRP than Western populations\(^16\),\(^17\). It has not been well investigated whether the association is modified by sex, overweight, hypertension, and smoking status, although hs-CRP levels vary with these factors\(^16\),\(^17\).

To examine the association between the serum hs-CRP levels and risk of atrial fibrillation and to assess the interactions by sex, overweight, hypertension, and smoking status on the association, we conducted a long-term prospective study among Japanese men and women without atrial fibrillation enrolled in the Circulatory Risk in Communities Study (CIRCS).

Methods

Study Populations

The CIRCS is a community-based dynamic cohort study of cardiovascular risk factors in Japan, the details of which have been previously described\(^13\),\(^19\). The present study initially included 8257 participants aged 40–79 years in three communities under the CIRCS—Ikawa town, Akita Prefecture (a northwest rural community); Minami-Takayasu district, Yao City, Osaka Prefecture (a mid-western suburb); and Kyowa district, Chikusei City, Ibaraki Prefecture (a mid-eastern rural community); baseline surveys were conducted in 2002–2007 in Ikawa, 2003–2008 in Minami-Takayasu, and 2002 in Kyowa. Initially, individuals were excluded if they had missing data on the hs-CRP levels (\(n = 2\)) or had hs-CRP levels of \(\geq 10.0\) mg/L (\(n = 160\)), had atrial fibrillation (\(n = 89\)) or cardiovascular disease including stroke and heart disease (\(n = 783\)), or had never undergone the annual health checkup after the beginning of the follow-up period in the present study (\(n = 706\)). Finally, a total of 6517 individuals (2,434 men and 4,083 women) were enrolled in the present study (Fig. 1). The protocol was approved by the Ethics Committees of Osaka University, University of Tsukuba, and Osaka Center for Cancer and Cardiovascular Disease Prevention.

Definition of Atrial Fibrillation and Follow Up

The annual cardiovascular disease risk surveys were conducted at each of the healthcare centers in the three communities during follow-up. The subjects were followed-up to determine the first incident of atrial fibrillation in the annual survey by the end of 2017 in Kyowa, 2018 in Ikawa, and 2019 in Minami-Takayasu, respectively. Standard 12-lead electrocardiograms (ECGs) were obtained from all participants in the supine position by well-trained technicians and coded using the Minnesota Code by well-trained physician-epidemiologists. Histories of physician-diagnosed atrial fibrillation were obtained by well-trained public health nurses. Atrial fibrillation was defined using Minnesota Codes 8-3-1 and/or information on history of physician-diagnosed atrial fibrillation from the surveys. We did not discriminate between paroxysmal and persistent atrial fibrillation. History of atrial fibrillation may include paroxysmal atrial fibrillation and a remote event of atrial fibrillation which had converted into sinus rhythm medically or through ablation procedures.

Baseline Examination

Blood was collected from the participants into plastic serum separator gel tubes while in the seated position. The serum was separated by centrifugation within 30 min of blood collection. The serum samples were placed on dry ice at the survey sites in Ikawa and Kyowa and stored at \(-80^\circ\)C until analysis. In Minami-Takayasu, the serum samples were stored under refrigeration until analysis and measured within a few days after the collection. The hs-CRP levels were measured in two laboratories, including the Osaka Medical Center for Health Science and Promotion (OMC), using the latex particle-enhanced immunonephelometric assay (BN ProSpec and BN II; Dade Behring Inc., Tokyo, Japan). The measurement accuracy of these instruments was validated using the international certified reference material for hs-CRP\(^21\) in the standardized CRP program at the OMC\(^22\). The measurement
limit range of the hs-CRP levels among the annual risk surveys was 0.149–0.170 mg/L; we treated the value of <0.170 mg/L as 0.170 mg/L in the present study. The body mass index (BMI) was calculated as weight in light clothing (kg) divided by height squared in stockmg feet (m²). Blood pressures in the right arm were measured by trained technicians using standard mercury sphygmomanometers and unified epidemiological methods. Hypertension was defined as systolic blood pressure of ≥ 140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg. Serum total cholesterol, triglycerides, HDL-cholesterol, and glucose levels were measured using enzymatic methods. The hemoglobin A1c (HbA1c) levels was measured using the latex agglutination immunoassay. When the triglycerides levels was less than 4.5 mmol/L (400 mg/dL), LDL-cholesterol was estimated by the Friedewald’s formula, as follows: Friedewald-estimated LDL-cholesterol = total cholesterol − (HDL-cholesterol + triglycerides/5). Borderline diabetes mellitus was defined as follows: (1) fasting serum glucose levels of 6.1–6.9 mmol/L (110–125 mg/dL), (2) non-fasting serum glucose levels of 7.7–11.1 mmol/L (140–199 mg/dL), and/or (3) HbA1c levels of 6.0%–6.4% (National Glycohemoglobin Standardization Program [NGSP]). Diabetes mellitus was defined as follows: (1) fasting serum glucose levels of ≥ 7.0 mmol/L (≥ 126 mg/dL), (2) non-fasting serum glucose levels of ≥ 11.1 mmol/L (≥ 200 mg/dL), (3) HbA1c levels of ≥ 6.5% (NGSP), and/or (4) initiation of therapeutic medicine for diabetes mellitus. The fasting state showed at least 8 hours after meals. Dyslipidemia was defined as follows: (1) Friedewald-estimated LDL-cholesterol of ≥ 3.6 mmol/L (≥ 140 mg/dL), (2) HDL-cholesterol < 1.0 mmol/L (≤ 40 mg/dL), (3) triglycerides ≥ 1.7 mmol/L (≥ 150 mg/dL), and/or (4) medication use for dyslipidemia. Each participant was interviewed to determine the number of cigarettes smoked per day, the weekly alcohol consumption in go-units (a Japanese traditional unit of volume equivalent to 23 g of ethanol), postmenopausal status for women, and medication use for hypertension, diabetes mellitus, and dyslipidemia.

**Statistical Analyses**

The values of the baseline characteristics according to the quintiles of hs-CRP levels were reported as means ± standard deviations for continuous variables and as percentages for categorical variables. And we used the analysis of covariance and the Cochran–Mantel–Haenszel test to compare among the quintiles of hs-CRP levels after adjustment for age, sex, and community. Person-years were calculated from the date of the baseline survey until diagnosis of atrial fibrillation or the final survey during follow-up, whichever came first.

Differences in the estimated cumulative hazard of atrial fibrillation according to the hs-CRP quintiles during follow-up were displayed using Kaplan–Meier curves with the log-rank test. The hazard ratios (HRs)
and 95% confidence intervals (CIs) for atrial fibrillation were calculated with reference to the lowest quintile of the hs-CRP levels using a Cox proportional hazard regression model stratified by community, and adjusted for age and sex and for other confounding variables, including BMI (kg/m²), hypertension (yes or no), serum total cholesterol levels (mg/dL), serum triglyceride levels (mg/dL), glucose levels category (normal, borderline, or diabetes mellitus), smoking status (non-current or current), alcohol intake status (never, former, <23 g/day, 23–46 g/day, 46–69 g/day, or ≥ 69 g/day), use of antihypertensive medication (yes or no), and dyslipidemia treatment use (yes or no). The reasons for the selection of the variables in the multivariable adjustment were as follows: (1) they were generally used in the previous studies which investigated the association between hs-CRP levels and the risk of atrial fibrillation and/or (2) they were themselves associated with risk of atrial fibrillation in each of univariate analyses by a Cox proportional hazard regression model in the present study.

The tests for the effect modification by sex, BMI (<25 or ≥ 25 kg/m²), blood pressure (non-hypertension or hypertension), and smoking status (non-current or current) were conducted with interaction terms generated by multiplying the dummy variable of hs-CRP in each quintile by sex (0 or 1), overweight (0 or 1), hypertension (0 or 1), or smoking status (0 or 1). P-values for the interactions were calculated by the likelihood ratio tests. Moreover, we calculate the HRs and 95% CIs stratified by these factors in the multivariable regression models with each interaction term via the hazardratio statement in proc phreg from the SAS Institute.

All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). P-values of < 0.05 were considered to indicate statistical significance on two-tailed analyses.

**Table 1.** Baseline characteristics of persons according to the quintiles of hs-CRP levels

| Quintiles of hs-CRP levels | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P value for difference* |
|-----------------------------|-------------|----|----|----|--------------|------------------------|
| Median hs-CRP (range), mg/L | 0.17 (0.17-0.19) | 0.28 (0.20-0.36) | 0.48 (0.37-0.60) | 0.80 (0.61-1.16) | 2.04 (1.17-9.83) |             |
| No. of persons              | 1312        | 1310 | 1284 | 1304 | 1307         |             |
| Men, %                      | 29.4        | 34.3 | 39.0 | 39.9 | 44.2         | <0.001      |
| Age, years                  | 56.7 ± 10.1 | 58.7 ± 9.5 | 60.4 ± 9.1 | 60.4 ± 9.3 | 61.3 ± 9.4 | <0.001      |
| Body mass index, kg/m²      | 21.8 ± 2.7  | 22.9 ± 2.8 | 23.6 ± 2.9 | 24.3 ± 3.2 | 24.8 ± 3.5 | <0.001      |
| Systolic blood pressure, mmHg | 124.9 ± 16.8 | 127.6 ± 16.8 | 130.5 ± 16.4 | 132.0 ± 17.4 | 133.2 ± 16.9 | <0.001      |
| Diastolic blood pressure, mmHg | 76.2 ± 10.3  | 77.5 ± 10.5 | 78.7 ± 10.6 | 79.6 ± 10.8 | 80.0 ± 10.6 | <0.001      |
| Use of antihypertensive medication, % | 11.4 | 15.2 | 20.3 | 24.2 | 26.6 | <0.001      |
| Hypertension, %             | 25.7        | 32.0 | 40.3 | 45.9 | 49.7         | <0.001      |
| HbAlc, %                    | 5.3 ± 0.7   | 5.4 ± 0.7 | 5.4 ± 0.7 | 5.5 ± 0.8 | 5.6 ± 0.9 | <0.001      |
| Serum glucose, mg/dL        | 100.0 ± 19.9 | 102.0 ± 25.7 | 103.4 ± 24.2 | 103.7 ± 22.0 | 105.4 ± 27.0 | 0.03        |
| Use of glucose-lowering medication, % | 2.5 | 3.4 | 3.8 | 3.3 | 4.7 | 0.41        |
| Diabetes mellitus, %        | 4.7         | 6.9 | 7.9 | 8.9 | 11.2        | <0.001      |
| Serum total cholesterol, mg/dL | 210.4 ± 34.6 | 215.4 ± 34.0 | 218.0 ± 34.8 | 219.6 ± 37.0 | 214.7 ± 36.3 | <0.001      |
| Serum triglycerides, mg/dL  | 88.3 ± 51.7 | 110.1 ± 76.1 | 119.0 ± 88.7 | 132.5 ± 84.3 | 134.6 ± 94.4 | <0.001      |
| Use of lipid-lowering medication, % | 5.5 | 6.7 | 10.1 | 8.7 | 10.3 | 0.001      |
| Dyslipidemia, %             | 40.5        | 52.5 | 58.5 | 63.0 | 62.4         | <0.001      |
| Current smokers, %          | 14.1        | 18.2 | 19.7 | 19.1 | 25.3         | <0.001      |
| Ethanol intake, g/day       | 7.7 ± 15.7  | 8.6 ± 17.2 | 10.5 ± 18.7 | 10.5 ± 19.6 | 11.4 ± 20.2 | 0.03        |
| Postmenopausal among women, % | 61.1        | 75.4 | 80.8 | 81.9 | 84.1         | <0.001      |

Values are reported as mean ± standard deviation or percentage.
*Adjusted for age, sex, and communities.

**Results**

Table 1 shows the baseline characteristics of 6,517 individuals (2,434 men and 4,083 women) according to the quintiles of the hs-CRP levels. The median hs-CRP levels was 0.47 mg/L (0.54 mg/L in men and 0.43 mg/L in women). Compared with individuals in the lowest quintile of hs-CRP levels, those who were in the second and higher quintiles of hs-CRP levels were more likely to be male, older, smoker, drinker, and high-risk individuals who suffered from hypertension, diabetes mellitus, and dyslipidemia, and to have higher means of BMI and the higher propor-
associated with increased risk of atrial fibrillation even after multivariable adjustment; persons with the second or higher quintiles of hs-CRP levels had two- to three-fold increased risk of atrial fibrillation compared with those with the lowest quintile. As shown in Fig. 3, these associations were similarly observed in both sexes (P for interaction=0.16), and did not vary by overweight, hypertension, and smoking status (P for interaction: P=0.71 for overweight, P=0.61 for hypertension, and P=0.87 for smoking status, respectively).

**Discussion**

Our long-term community-based prospective study showed that elevated hs-CRP levels were significantly associated with the risk of atrial fibrillation in the general Japanese population. Furthermore, the significant association was observed in both sexes. The effect modifications by sex, overweight, hypertension, and smoking status on the association were not observed although those without overweight, hypertension or smoking status had a stronger association than those with these factors.
Hazard ratios (95% confidence intervals) of the incident risk of atrial fibrillation according to the quintiles of hs-CRP levels

Table 2. Hazard ratios (95% confidence intervals) of the incident risk of atrial fibrillation according to the quintiles of hs-CRP levels

| Quintiles of hs-CRP levels | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) |
|---------------------------|-------------|----|----|----|--------------|
| No. of persons            | 1312        | 1310 | 1284 | 1304 | 1307         |
| No. of events             | 9           | 24  | 26  | 32  | 36           |
| Person-years              | 13978       | 13484 | 12543 | 12808 | 12209        |
| Crude incidence rate (/1000 person-years) | 0.6 | 1.8 | 2.1 | 2.5 | 2.9 |
| Age- and sex-adjusted HR (95%CI) | 1.00 | 2.60 (1.21-5.59) | 2.64 (1.23-5.64) | 3.31 (1.58-6.94) | 3.59 (1.73-7.48) |
| Multivariable HR (95%CI) | 1.00        | 2.54 (1.17-5.50) | 2.28 (1.06-4.93) | 2.92 (1.37-6.23) | 2.77 (1.30-5.91) |

1Adjusted for age, sex, body mass index, hypertension, serum total cholesterol, serum tryglycerides, serum glucose category, smoking status (non-current, current), ethanol intake (never, former, <23 g/day, 23-46 g/day, 46-69 g/day, ≥69 g/day), use of antihypertensive medication and dyslipidemia treatment.

To the best of our knowledge, our study is the first to investigate the association between the hs-CRP levels and the development of atrial fibrillation in the general Japanese population. Our findings were consistent with the findings of previous prospective studies in the USA, Denmark, Sweden, and South Korea, which reported that increased CRP levels is an independent risk marker for atrial fibrillation.10,11

Three previous cohort studies in the USA and Europe reported the following findings: in the Cardiovascular Health Study, individuals with the highest quartile of hs-CRP levels (≥3.41 mg/L) had a higher risk of atrial fibrillation than those with the lowest quartile (<0.97 mg/L) among 5491 elderly American men and women (median follow-up duration of 8 years);10 in the Copenhagen City Heart Study, individuals with the highest quintile of hs-CRP levels (≥3.6 mg/L) had a higher risk than those with the lowest quintile (<1.2 mg/L) among 10,276 middle-aged men and women (median follow-up duration of 14 years);11 in the Women’s Health Study, women with the highest tertile of hs-CRP levels (≥3.4 mg/L) had a higher risk than those with the lowest tertile (≤1.1 mg/L) among 24,734 middle-aged health professionals (median follow-up duration of 14 years).12 These previous studies have further reported that moderate hs-CRP levels (0.97–3.41, 1.1–3.4, and 1.2–3.6 mg/L, respectively) were not associated with an excess risk of atrial fibrillation.9,11,12 However, in the present study, we found that not only individuals with the highest quintile of hs-CRP levels (≥1.17 mg/L) but also those with low-to-moderate hs-CRP levels of ≥0.20 mg/L had a higher risk of atrial fibrillation than those with the lowest quintile (≤0.19 mg/L). Our results were consistent with the findings from the South Korean study;14 individuals with the highest hs-CRP levels of ≥1.1 mg/L but also those with moderate hs-CRP levels of 0.3–0.4 mg/L had a significantly higher risk of atrial fibrillation than those with the lowest hs-CRP levels of <0.3 mg/L. The median hs-CRP levels in the Japanese and Korean populations was much lower than that in Western countries.14,16,17 Our subjects with hs-CRP levels of >3.0 mg/L accounted for only 6.0% of the total subjects, which was under one-third of the proportion in Western populations.9,11,12 Another South Korean study15 showed that a high CRP level at a single measurement (≥1.0 or >3.0 mg/L; the cut off points propounded by the workshop of CDC/AHA in 2002 24) was not associated with the risk of atrial fibrillation. From these results, the hs-CRP levels cut-off point to predict risk of atrial fibrillation in the Asian population may be less than 1.0 mg/L and be much lower than that of the Western population.

A potential mechanism for the development of atrial fibrillation by inflammation was suggested based on an animal experimental study; the infiltration of mast cells, key mediators of allergic and immune responses, into the atrium of a pressure-overloaded heart increases the production of platelet-derived growth factor A, which in turn promotes atrial structural remodeling and enhanced atrial fibrillation.25 However, the mechanism by which a systemic low-grade inflammation (hs-CRP levels of <10 mg/L) causes atrial fibrillation remained uncertain. Marott et al. suggested that elevated plasma CRP levels per se did not increase the risk of atrial fibrillation in their Mendelian randomization study of 47,000 individuals based on the finding that genetically elevated CRP levels were not associated with the risk of atrial fibrillation.14. Thus, the CRP levels might be a predictive marker of the risk of atrial fibrillation rather than a causative factor.

Several previous studies have suggested that inflammation is a consequence of atrial fibrillation.26,28 Induction of atrial fibrillation led to the increment of serum CRP levels at 6 and 24 hours in the patients.26 CRP may act as an opsonin and partic-
Fig. 3. Forest plot for the multivariable hazard ratios (95% confidence intervals) of the association between hs-CRP level quintiles and risk of atrial fibrillation, stratified by sex, body mass index (<25 or ≥25 kg/m²), blood pressure (non-hypertension or hypertension) and smoking status (non-current smoker or current smoker), by using a Cox proportional hazard regression model with interaction term. All models were adjusted for age, sex, body mass index, hypertension, serum total cholesterol, serum triglycerides, serum glucose category, smoking status, ethanol intake, use of antihypertensive medication and dyslipidemia treatment use, and each interaction term was included into the multivariable adjustment. In strata of overweight status, the body mass index variable was replaced with the binary variable (<25 or ≥25 kg/m²). P-values were calculated by the likelihood ratios for the interaction terms between all strata and the quintiles of hs-CRP levels.

ipate in the clearance of apoptotic myocytes \(^{27}\) in overloaded atria induced by atrial fibrillation \(^{28}\). Patients with persistent atrial fibrillation showed higher mean CRP levels at baseline, which continued to be elevated for 1 year, while patients with paroxysmal atrial fibrillation had decreased mean CRP levels at 30 days and 1 year from the baseline \(^{29}\).

The strengths of our study are that it was a long-term, population-based cohort study with a high follow-up rate. Therefore, our findings could be extrapolated to general Japanese and other Asian populations.

Our study also has several limitations. First, some
misclassification of the hs-CRP levels, i.e., regression dilution bias, needs to be considered because we divided into quintile by the single measurement value of the hs-CRP at baseline. The intraclass correlation coefficient of the log-transformed hs-CRP levels between baseline and the following one year was 0.57 among the individuals who underwent hs-CRP levels measurement for the second consecutive year in our sub sample study ($n=3,253$), which indicated a moderate positive correlation between them.

Therefore, the misclassification of hs-CRP levels would not have a large impact on the present study results. Second, we could not detect paroxysmal atrial fibrillation systematically because we obtained the finding of atrial fibrillation from annual risk surveys. Third, we may have underestimated the number of subjects with atrial fibrillation because some of them may have not reported a history of atrial fibrillation during the surveys. However, the likelihood of the underestimation would be non-differential according to hs-CRP levels and therefore the association was unlikely affected. Fourth, confounding effects by misclassified or unmeasured covariates may remain due to the observational nature of the study. Fifth, we have no good explanation for the increased risk of atrial fibrillation in individuals with apparently normal range of hs-CRP levels, i.e., its second quintile. Further studies will be needed to confirm the hs-CRP levels cut-off to predict increased risk of atrial fibrillation in Asian populations.

**Conclusion**

The hs-CRP levels were positively associated with the risk of atrial fibrillation in the general Japanese population. This association did not vary by sex, overweight, hypertension, and smoking status.

**Acknowledgements**

The authors thank the CIRCS investigators listed in ref. 20. The authors also thank the research staff of Osaka Center for Cancer and Cardiovascular Disease Prevention and health professionals in the survey communities for their research assistance, Professor Satoshi Hattori for his statistical advice and our colleagues from Osaka University Center of Medical Data Science and Advanced Clinical Epidemiology Investigator’s Research Project for providing their insight and expertise for our research.

**Sources of Funding**

This research was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP19ek0210082 and a Grant-in-Aid for Scientific Research B (grant number 15H04775) from the Japan Society for the Promotion of Science.

**Conflict of Interest**

The authors report no conflict of interest.

**References**

1) Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991; 22: 983-988
2) Hu WS, Lin CL: Risk of Atrial Fibrillation in Patients with Congenital Heart Disease: Results of a Propensity Score-Matched, Nationwide Cohort Study. J Atheroscler Thromb, 2019; 26: 670-677
3) Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998; 98: 946-952
4) Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA: Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ, 2016; 354: i4482
5) Kodani E, Atarashi H: Prevalence of atrial fibrillation in Asia and the world. J Arrhythm, 2012; 28: 330-337
6) Rahman F, Kwan GF, Benjamin EJ: Global epidemiology of atrial fibrillation. Nat Rev Cardiol, 2014; 11: 639-654
7) Sakata K, Gamou T, Tada H, Hayashi K, Ino H, Yamagishi M, Masaaki Kawashiri, behalf of the MILLION Study Group: Low Baseline High-Sensitive C-Reactive Protein is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study. J Atheroscler Thromb, 2019; 26: 442-451
8) Chei CL, Yamagishi K, Kitamura A, Kiyama M, Imano H, Ohira T, Cui R, Tanigawa T, Sankai T, Ishikawa Y, Sato S, Iso H: C-reactive protein levels and risk of stroke and its subtype in Japanese: The Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2011; 217: 187-193
9) Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK: Inflammation as a risk factor for atrial fibrillation. Circulation, 2003; 108: 3006-3010
10) Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Tofler GH, Selhub J, Jacques PF, Wolf PA, Magnani JW, Ellinor PT, Wang TJ, Levy D, Vasan RS, Benjamin EJ: Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation, 2010; 121: 200-207
11) Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, Benn M: Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general
population. J Am Coll Cardiol, 2010; 56: 789-795
12) Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, Buring JE, Albert CM: A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J, 2010; 31: 1730-1736
13) Smith JG, Newton-Cheh C, Almgren P, Struck J, Morganthaler NG, Bergmann A, Platonov PG, Hedblad B, Engstroem G, Wang T, Melander O: Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol, 2010; 56: 1712-1719
14) Kwon CH, Kang JG, Lee HJ, Kim NH, Sung JW, Cheong E, Sung KC: C-reactive protein and risk of atrial fibrillation in East Asians. Europace, 2017; 19: 1643-1649
15) Lee Y, Park HC, Shin JH, Lim YH, Shin J, Park JK: Single and persistent elevation of C-reactive protein levels and the risk of atrial fibrillation in a general population: The Ansan-Ansung Cohort of the Korean Genome and Epidemiology Study. Int J Cardiol, 2019; 277: 240-246
16) Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E: Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol, 2001; 153: 1183-1190
17) Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, Sternefeld B, Pasternak RC, Chae CU; SWAN Investigators: Ethnic differences in C-reactive protein concentrations. Clin Chem, 2008; 54: 1027-1037
18) Saito I, Sato S, Nakamura M, Kokubo Y, Mannami T, Adachi H, Konishi M, Okada K, Ito H, Kario K, Ohitsu F, Momiyama Y, Tsushima M: A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) study. Atherosclerosis, 2007; 194: 238-244
19) Imano H, Kitamura A, Sato S, Kiyama M, Ohira T, Yamagishi K, Noda H, Tanigawa T, Iso H, Shimamoto T: Trends for blood pressure and its contribution to stroke incidence in the middle-aged Japanese population: the Circulatory Risk in Communities Study (CIRCS). Stroke, 2009; 40: 1571-1577
20) Yamagishi K, Muraki I, Kubota Y, Hayama-Terada M, Imano H, Cui R, Umesawa M, Shimizu Y, Sankai T, Okada T, Sato S, Kitamura A, Kiyama M, Iso H: The Circulatory Risk in Communities Study (CIRCS): A Long-Term Epidemiological Study for Lifestyle-Related Disease Among Japanese Men and Women Living in Communities. J Epidemiol, 2019; 29: 83-91
21) Kimberly MM, Vesper HW, Caudill SP, Cooper GR, Rifai N, Dati F, Myers GL: Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem, 2003; 49: 611-616
22) Nakamura M, Sato S, Shimamoto T: Establishment of external quality control program for hs-CRP and three-year follow-up of the performance for precision and accuracy. J Atheroscler Thromb, 2007; 14: 287-293
23) Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
24) Pearson TA, Mensah GA, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107: 499-511
25) Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, Yamamoto R, Ozasa Y, Fujimoto M, Wang P, Nakauchi H, Nakaya H, Komuro I: Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest, 2010; 120: 242-253
26) Pirat B, Atar I, Ertan C, Bozbas H, Gulmez O, Muderisoglu H, Ozin B: Comparison of C-reactive protein levels in patients who do and do not develop atrial fibrillation during electrophysiologic study. Am J Cardiol, 2007; 100: 1552-1555
27) Mukaka MM: Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J, 2012; 24: 69-71